Harvard Apparatus Regenerative Technology, Inc.
For the period ended Sep 30, 2025. Filed Nov 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 7, 2025
HRGNStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’** EQUITY (DEFICIT)**
(in thousands, except share data)
| Number of · Accumulated | ||||||
|---|---|---|---|---|---|---|
| Common · Additional · Other · Total | ||||||
| Shares | Common | Paid-in | Accumulated | Comprehensive | Stockholders’ | |
| Outstanding | Stock | Capital | Deficit | Loss | Equity | |
| Balance at July 1, 2025 | 15,918,979 | $159 | $103,779 | $(103,170) | $(7) | $761 |
| Share-based compensation expense | — | — | 495 | — | — | 495 |
| Issuance of common stock | 1,250,000 | 13 | 1,987 | — | — | 2,000 |
| Net loss | — | — | — | (1,700) | — | (1,700) |
| Other comprehensive loss | — | — | — | — | (2) | (2) |
| Balance at September 30, 2025 | 17,168,979 | $172 | $106,261 | $(104,870) | $(9) | $1,554 |
| Number of · Accumulated · Total | ||||||
|---|---|---|---|---|---|---|
| Common · Additional · Other · Stockholders’ | ||||||
| Shares | Common | Paid-in | Accumulated | Comprehensive | Equity | |
| Outstanding | Stock | Capital | Deficit | Loss | (Deficit) | |
| Balance at July 1, 2024 | 14,315,091 | $143 | $96,073 | $(96,484) | $(22) | $(290) |
| Share-based compensation expense | — | — | 562 | — | — | 562 |
| Issuance of common stock | 1,388,888 | 14 | 4,986 | — | — | 5,000 |
| Issuance of common stock from exercise of warrants | 215,000 | 2 | 428 | — | — | 430 |
| Net loss | — | — | — | (1,860) | — | (1,860) |
| Other comprehensive loss | — | — | — | — | (2) | (2) |
| Balance at September 30, 2024 | 15,918,979 | $159 | $102,049 | $(98,344) | $(24) | $3,840 |
| Number of · Accumulated | ||||||
|---|---|---|---|---|---|---|
| Common · Additional · Other · Total | ||||||
| Shares | Common | Paid-in | Accumulated | Comprehensive | Stockholders’ | |
| Outstanding | Stock | Capital | Deficit | Loss | Equity | |
| Balance at January 1, 2025 | 15,918,979 | $159 | $102,757 | $(99,688) | $(6) | $3,222 |
| Share-based compensation expense | — | — | 1,517 | — | — | 1,517 |
| Issuance of common stock | 1,250,000 | 13 | 1,987 | — | — | 2,000 |
| Net loss | — | — | — | (5,182) | — | (5,182) |
| Other comprehensive loss | — | — | — | — | (3) | (3) |
| Balance at September 30, 2025 | 17,168,979 | $172 | $106,261 | $(104,870) | $(9) | $1,554 |
| Number of · Accumulated | ||||||
|---|---|---|---|---|---|---|
| Common · Additional · Other · Total | ||||||
| Shares | Common | Paid-in | Accumulated | Comprehensive | Stockholders’ | |
| Outstanding | Stock | Capital | Deficit | Loss | Equity | |
| Balance at January 1, 2024 | 13,947,324 | $139 | $93,463 | $(91,956) | $— | $1,646 |
| Share-based compensation expense | — | — | 1,694 | — | — | 1,694 |
| Issuance of common stock | 1,756,655 | 18 | 6,464 | — | — | 6,482 |
| Issuance of common stock from exercise of warrants | 215,000 | 2 | 428 | — | — | 430 |
| Net loss | — | — | — | (6,388) | — | (6,388) |
| Other comprehensive loss | — | — | — | — | (24) | (24) |
| Balance at September 30, 2024 | 15,918,979 | $159 | $102,049 | $(98,344) | $(24) | $3,840 |
See accompanying notes to unaudited condensed consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.